G6PD and Plasmodium vivax malaria: Accordingly, it is likely that the stringent safety regulations for tafenoquine will mean that few patients with vivax malaria will be able to receive it.21 If deemed safe and appropriate, sex-based treatment strategies have potential to be cost-effective, particularly in settings where the G6PD RDT is accessible at a low cost.